Hubei Marvel-Bio Medicine

Hubei Marvel-Bio Medicine is a clinical-stage biotechnology company based in China that focuses on the development of innovative small molecule therapeutics for neurological disorders and oncology. The company's lead program, HG101, is a first-in-class small molecule inhibitor targeting the xCT (SLC7A11) transporter, which plays a critical role in regulating glutamate levels and oxidative stress. Currently, the firm is advancing its pipeline through clinical trials for indications including Amyotrophic Lateral Sclerosis (ALS) and various solid tumors such as glioblastoma. By leveraging its expertise in medicinal chemistry and disease biology, Hubei Marvel-Bio Medicine aims to address significant unmet medical needs in the fields of neurodegeneration and cancer.